Multimode optical imaging for translational chemotherapy: in vivo tumor detection and delineation by targeted gallium corroles
Abstract
We report the feasibility of tumor detection and delineation in vivo using multimode optical imaging of targeted gallium corrole (HerGa). HerGa is highly effective for targeted HER2+ tumor elimination in vivo, and it emits intense fluorescence. These unique characteristics of HerGa prompted us to investigate the potential of HerGa for tumor detection and delineation, by performing multimode optical imaging ex vivo and in vivo; the imaging modes included fluorescence intensity, spectral (including ratiometric), lifetime, and two-photon excited fluorescence, using our custombuilt imaging system. While fluorescence intensity imaging provided information about tumor targeting capacity and tumor retention of HerGa, ratiometric spectral imaging offered more quantitative and specific information about HerGa location and accumulation. Most importantly, the fluorescence lifetime imaging of HerGa allowed us to discriminate between tumor and non-tumor regions by fluorescence lifetime differences. Finally, two-photon excited fluorescence images provided highly resolved and thus topologically detailed information around the tumor regions where HerGa accumulates. Taken together, the results shown in this report suggest the feasibility of tumor detection and delineation by multimode optical imaging of HerGa, and fluorescent chemotherapy agents in general. Specifically, the multimode optical imaging can offer complementary and even synergetic information simultaneously in the tumor detection and delineation by HerGa, thus enhancing contrast.
Additional Information
© 2011 SPIE. Partial support from the US Navy Bureau of Medicine and Surgery is gratefully acknowledged. This work was partially supported by grants from the NIH (R21 CA116014, R01 CA102126, R01 CA129822, and R01 CA140995), the DoD (BC050662), the Susan G. Komen Breast Cancer foundation (BCTR0201194), and the Donna and Jesse Garber Award. Work at Caltech was supported by NIH DK019038 and the Arnold and Mabel Beckman Foundation. Work at the Technion was supported by The Herbert Irving Cancer and Atherosclerosis Research Fund.Attached Files
Published - 79020F_1.pdf
Files
Name | Size | Download all |
---|---|---|
md5:8cf190d784c01d91de7b0eda9da3f789
|
484.5 kB | Preview Download |
Additional details
- PMCID
- PMC4582672
- Eprint ID
- 73420
- Resolver ID
- CaltechAUTHORS:20170111-103042462
- US Navy Bureau of Medicine and Surgery
- NIH
- R21 CA116014
- NIH
- R01 CA102126
- NIH
- R01 CA129822
- NIH
- R01 CA140995
- Department of Defense
- BC050662
- Susan G. Komen Breast Cancer Foundation
- BCTR0201194
- Donna and Jesse Garber Award
- NIH
- DK019038
- Arnold and Mabel Beckman Foundation
- Herbert Irving Cancer and Atherosclerosis Research Fund
- Created
-
2017-01-21Created from EPrint's datestamp field
- Updated
-
2021-11-11Created from EPrint's last_modified field
- Series Name
- Proceedings of SPIE
- Series Volume or Issue Number
- 7902